R.M. Califf

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

Eric J. Topol, R.M. Califf, Harlan F. Weisman et al. · The Lancet · 1994 · 840 citations

Percutaneous Coronary Intervention, Thrombosis, Cardiovascular Disease +15

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

James E. Tcheng, Stephen G. Ellis, Barry S. George et al. · Circulation · 1994 · 414 citations · Full text

End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators

RQ Migrino, JB Young, SG Ellis et al. · Circulation · 1997 · 178 citations

Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals

Stuart J. Connolly, Salim Yusuf, Karl Swedberg et al. · Journal of Hypertension · 2011 · 114 citations

Medicine, Metronomic Therapy, Clinical Trials +5

Role of diuretics,   blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study

Long Shen, Bimal Shah, Eric Reyes et al. · BMJ · 2013 · 114 citations · Full text